POMDOCTOR Partners with Pharma Firms to Accelerate Internet Hospital Growth, Projecting RMB 71.8 Billion in Drug Sales by 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: PRnewswire
- Strategic Collaboration: POMDOCTOR has entered into agreements with several domestic pharmaceutical companies to introduce innovative drugs on its internet hospital platform, which is expected to significantly enhance the company's competitiveness in the rapidly growing online healthcare market.
- Massive Market Potential: According to Yaozh.com, China's online drug sales market has grown from RMB 19 billion in 2020 to RMB 60.8 billion in 2023, with projections of reaching RMB 71.8 billion in 2024, reflecting a compound annual growth rate of 39.4%, providing ample growth opportunities for POMDOCTOR.
- Innovative Sales Channels: The partnerships not only provide patients with access to advanced treatment options but also create efficient sales channels for pharmaceutical companies, enhancing overall profitability and market presence for POMDOCTOR.
- Supply Chain Optimization: POMDOCTOR's flexible collaboration model reduces reliance on traditional distributors, enhances channel control, and improves cash flow efficiency, driving the modernization of the pharmaceutical supply chain.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
